login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News
USA
- NASDAQ:ALNY -
US02043Q1076
-
Common Stock
449.16
USD
-4.81 (-1.06%)
Last: 11/14/2025, 8:00:00 PM
449.16
USD
0 (0%)
After Hours:
11/14/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALNY Latest News, Press Relases and Analysis
All
Press Releases
17 days ago - By: Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings
4 days ago - By: Benzinga
- Mentions:
NVO
PFE
PRTA
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
5 days ago - By: The Motley Fool
- Mentions:
TOST
IONQ
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money
8 days ago - By: Alnylam Pharmaceuticals, Inc.
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
9 days ago - By: Benzinga
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
9 days ago - By: Investor's Business Daily
- Mentions:
RY
RY.CA
NTLA
CRSP
...
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies
12 days ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
16 days ago - By: Zacks Investment Research
- Mentions:
BEAM
FOLD
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
17 days ago - By: Zacks Investment Research
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
17 days ago - By: Investor's Business Daily
- Mentions:
PFE
BBIO
IONS
AZN
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
17 days ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
18 days ago - By: Zacks Investment Research
- Mentions:
VRTX
ZTS
EXAS
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
24 days ago - By: Zacks Investment Research
- Mentions:
ALKS
VKTX
HOWL
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
24 days ago - By: Zacks Investment Research
- Mentions:
ADPT
IQV
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
24 days ago - By: Zacks Investment Research
- Mentions:
ARVN
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
24 days ago - By: Zacks Investment Research
- Mentions:
REGN
ETNB
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
a month ago - By: Zacks Investment Research
Why Alnylam (ALNY) Might be Well Poised for a Surge
a month ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
a month ago - By: DataM Intelligence 4 Market Research LLP
Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence
2 months ago - By: Bloomberg
- Mentions:
BMY
ABBV
Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots
2 months ago - By: Zacks Investment Research
- Mentions:
NVS
PFE
BBIO
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
2 months ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
2 months ago - By: Alnylam Pharmaceuticals, Inc.
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
2 months ago - By: Investor's Business Daily
- Mentions:
XPH
PPH
XBI
IBB
...
Pharma Tariffs Back In Spotlight On New Trump Threat
2 months ago - By: Illumina, Inc.
- Mentions:
ILMN
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Please enable JavaScript to continue using this application.